A recent study indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who end conventional diet and exercise regimens.
Research printed in a leading medical journal shows that while overweight people can lose a large proportion of their body weight while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users using these treatments must be cognizant of the potential of quick rebound weight gain when the medication ends," cautioned expert Dr. Susan Jebb.
This pace of regain means a reversion to pre-treatment mass in about a year and a half.
Comparing Therapies
The study, which reviewed 37 of trials involving over 9,000 of participants, compared the effects of these new drugs with older methods.
Researchers point out that people who shed pounds through diet and exercise usually experience a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Explaining the Fast Rebound
Experts suggest the mechanism of the drugs is key to understanding the amplified regain.
The injections copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous hormone, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Health authorities suggest the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the high risk of relapse, the therapy might need to be ongoing.
This perspective is supported by drug manufacturers, who state that the results "highlight the chronic character of excess weight," akin to managing conditions like diabetes.
Patient Experiences
Individuals who have discontinued the medication describe a sudden return of hunger.
"I experienced a trigger that goes on and I was suddenly starving," said one woman.
This challenge is worsened if patients have not developed permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the medications through private prescriptions rather than public health services.
Finally, clinicians stress that while the jabs are powerful agents for weight loss, they are not a permanent cure and lasting health benefits hinges on combined lifestyle changes.
